Whistleblower Can't Fight Amgen's $612M Aranesp Deal: Judge

Law360, New York (January 3, 2013, 4:09 PM EST) -- A New York federal judge on Wednesday denied a whistleblower's bid to challenge Amgen Inc.'s $612 million civil settlement over misbranding its Aranesp anemia drug, part of a combined $762 million in criminal and civil penalties shelled out by the biotech giant.

Dr. Joseph Piacentile, one of several people to launch qui tam suits accusing Amgen of violating the federal False Claims Act and similar state statutes by improperly promoting off-label use of Aranesp and giving doctors kickbacks to prescribe it to patients, said he didn't...
To view the full article, register now.